Industry to undertake increasingly mature Huahai pharmaceutical products patent expired

Huahai Pharmaceutical (600521) internationalization process is still in progress. The company announced yesterday that it had signed a strategic agreement with the international pharmaceutical giant Novartis, the Irish Division and its subsidiaries, to supply the APIs and intermediates to Novartis's global affiliates, and to supply it with a range of products for its commercialization and development phase,　　The two sides agreed to continue to discuss the product list in the discussion. The specific situation of the strategic cooperation, Novartis pharmaceutical related people in the securities Times interviewed by reporters did not give a clear response. However, China Sea pharmaceutical industry dong Shu Yonghua told reporters that the agreement for 5 years, the two sides will be in accordance with the global share of drugs involved in the formulation of specific supply ratio, in the long run, will greatly enhance the performance of the company, and from the former pharmaceutical manufacturers to supply raw materials to now become the original research drugs, patent medicine manufacturers suppliers,　　The strategic cooperation Agreement will become the comprehensive strength of Huahai pharmaceutical industry a turning point.　　At present, Huahai pharmaceutical foreign business accounted for the proportion between 70% to 80%, for this and Novartis's strategic cooperation will further enhance the proportion of foreign business, Shu Yonghua said, the company vigorously develop foreign markets, but also actively explore the domestic market.　　For the Huahai pharmaceutical industry, China and the pharmaceutical industry researcher Lio Van to reporters, this shows that Huahai pharmaceutical industry to further increase the cooperation with patent pharmaceutical enterprises, the opportunity to undertake industrial transfer is maturing. According to its introduction, because of cost control, the international pharmaceutical giants are looking for ways to reduce procurement costs, and the transfer of manufacturing to Low-cost and quality assurance of countries or regions is the choice. Huahai Pharmaceuticals is China's first pharmaceutical company certified by FDA cGMP and obtained anda. Currently has 8 anda in the United States, of which 2 are autonomous declarations, in Europe has obtained 2 document number, and 9 are in the application, the company's current business scope reached 25 countries, In the international network has a certain advantages and brand advantages, nature has become the international enterprise Giants to seek industrial transfer of cooperation objects. At present, including Novartis Pharmaceutical, Bringhe Ingham, AstraZeneca, Merck and other well-known enterprises have the intention to cooperate or have signed a cooperation agreement.　　Shu Yonghua also told reporters that in addition to the establishment of cooperation with Merck and Novartis, there are still some projects in the Chinese sea pharmaceutical industry. Lio Van also said that through the strategic cooperation, Huahai pharmaceutical industry, the Pulitzer type of raw materials, the bulk of the drug, the company is expected to usher in performance turning point. At present, Novartis's cardiovascular products mainly include double bot (Valsartan/amlodipine), Diovan/Complex Diovan (Valsartan), Lotensin New (Benazepril), the cardiovascular products of the main include Captopril tablets, Shantan (Losartan).　　Prior to this, Huahai has signed a transfer production agreement and a supply agreement with Novartis and Texaco, the establishment of the strategic partnership indicates that Huahai Pharmaceutical will become the major supplier of raw materials for Novartis and Texaco products to meet the needs of its production and sales in China. According to its introduction, NovartisThe annual sales income of the Losartan products is about 7 billion U.S. dollars, the patent will expire next year, and the main direction of cooperation between Huahai pharmaceutical and international pharmaceutical giant is the patent expired drugs. Shu Yonghua said, on the cooperation of the products of the Losartan, the company is still in talks with Novartis.